title: Influence of progesterone withdrawal on pregnancy-related parameters during post-implantation early pregnancy loss.
abstract: Pharmacologically-induced luteolysis or treatment with an antiprogestin in early post-implantation pregnancy in dogs results in asynchronous death and resorption of conceptuses, indicating variable rates of response of individual conceptuses towards progesterone deficiency. This variability also seems to occur in bitches showing pregnancy failure in response to spontaneous luteal deficiency. In a total of 10 beagle pregnancies (two consecutive pregnancies of five bitches), abortifacient treatments beginning on day 24 after ovulation (ov) involved either administration of a progestin antagonist (total of six pregnancies, in three bitches) or a luteolytic regimen of prostaglandin F(2alpha)-analogue together with a dopamine agonist (total of four pregnancies, in two bitches). The outcomes were evaluated in relation to four control pregnancies in two bitches by assay of serum progesterone, prolactin and relaxin at selected time points or within selected time periods, by ultrasound of conceptuses including measurement of uterine blood flow, and parameters of the blood fibrinolytic system including plasma fibrinogen and plasminogen. The process of embryonic death and conceptus resorption was variable in onset and duration both in bitches that received the progesterone antagonist aglepristone (AGLE) and in those under the luteolytic treatment (cloprostenol combined with cabergoline). Pregnancy termination (death of all embryos or foetuses, respectively) occurred as early as day 29 and as late as day 41 after ov in AGLE-treated bitches, and not earlier than day 37 after ov in luteolytic-treatment bitches. Impending embryonic death was not predicted by changes in relaxin concentration, parameters of the fibrinolytic system, or in the perfusion of small uteroplacental vessels.
authors.affiliation: Unit for Reproductive Medicine of Clinics - Small Animal Clinic, Hannover, Germany. Anne-Rose.Guenzel-Apel@tiho-hannover.de
authors.forename: A R
authors.initials: AR
authors.lastname: Günzel-Apel
authors.forename: T
authors.initials: T
authors.lastname: Höftmann
authors.forename: S
authors.initials: S
authors.lastname: Nottorf
authors.forename: E
authors.initials: E
authors.lastname: Politt
authors.forename: A
authors.initials: A
authors.lastname: Meyer-Lindenberg
authors.forename: H O
authors.initials: HO
authors.lastname: Hoppen
authors.forename: A
authors.initials: A
authors.lastname: Einspanier
authors.forename: H M
authors.initials: HM
authors.lastname: Knijn
authors.forename: R
authors.initials: R
authors.lastname: Mischke
mesh_terms: D000028:Abortion, Induced / Q000662:veterinary; D000034:Abortion, Veterinary; D000818:Animals; D000077465:Cabergoline; D003008:Cloprostenol / Q000008:administration & dosage / Q000494:pharmacology; D004285:Dogs; D047108:Embryonic Development; D004873:Ergolines / Q000008:administration & dosage / Q000494:pharmacology; D004963:Estrenes / Q000008:administration & dosage / Q000494:pharmacology; D005260:Female; D011247:Pregnancy; D011270:Pregnancy, Animal; D011374:Progesterone / Q000097:blood*; D011388:Prolactin / Q000097:blood; D012065:Relaxin / Q000097:blood
chemical_list: D004873:Ergolines; D004963:Estrenes; C419063:aglepristone; D003008:Cloprostenol; D011374:Progesterone; D011388:Prolactin; D012065:Relaxin; D000077465:Cabergoline